轻度非心源性栓塞性卒中后双联抗血小板治疗的决定因素与时间趋势
本研究基于佛罗里达卒中登记处168家医院2010年1月至2022年9月的数据,纳入72 597例轻型非心源性栓塞性缺血性卒中(NCIS)患者,分析出院时双联抗血小板治疗(DAPT)处方的时间趋势和决定因素。结果显示DAPT处方率从2010年的25.7%上升至2022年的52.8%,但仍有大量患者未接受循证DAPT治疗,且存在显著的卒中照护差异。
要点
- 2010至2022年,轻型NCIS患者出院DAPT处方率从25.7%升至52.8%。
- 既往抗血小板治疗、大动脉粥样硬化、糖尿病和高脂血症与DAPT处方正相关。
- 女性、非西班牙裔黑人、就诊于可取栓卒中中心等与未接受DAPT相关。
核心结论
- 尽管轻型NCIS后DAPT处方呈时间上升趋势,但循证DAPT仍存在显著未充分利用,并与卒中照护的显著差异相关。
研究设计与样本
- 本研究为队列研究的横断面分析,纳入佛罗里达卒中登记处168家参与“Get With The Guidelines-Stroke”医院2010年1月至2022年9月间收治的轻型NCIS(NIHSS评分≤3)且可能适合DAPT的患者。
- 最终样本为72 597例轻型NCIS患者,平均年龄68±14岁,女性占47.3%。
主要发现
- 在72 597例轻型NCIS患者中,24 693例(34.0%)出院时接受DAPT,47 904例(66.0%)接受单联抗血小板治疗。
- DAPT处方率从2010年的25.7%上升至2022年的52.8%(β/年 2.5% [95% CI, 1.5%-3.4%])。
- 与DAPT处方相关的因素包括:病前抗血小板治疗(aOR, 4.66 [95% CI, 2.20-9.88])、大动脉粥样硬化(aOR, 1.68 [95% CI, 1.43-1.97])、糖尿病(aOR, 1.29 [95% CI, 1.13-1.47])和高脂血症(aOR, 1.24 [95% CI, 1.10-1.39])。
- 与未接受DAPT相关的因素包括:女性(aOR, 0.83 [95% CI, 0.75-0.93])、非西班牙裔黑人(相比非西班牙裔白人;aOR, 0.78 [95% CI, 0.68-0.90])、入住可取栓卒中中心(相比综合卒中中心;aOR, 0.78 [95% CI, 0.66-0.92])、就诊时间距最后正常时间1至7天(相比<24小时;aOR, 0.86 [95% CI, 0.76-0.96])以及小血管病卒中(aOR, 0.81 [95% CI, 0.72-0.94])。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Short-term dual antiplatelet therapy (DAPT) reduces early stroke recurrence after mild noncardioembolic ischemic stroke (NCIS). We aim to evaluate temporal trends and determinants of DAPT prescription after mild NCIS in the Florida Stroke Registry, a statewide registry across Get With The Guidelines-Stroke participating hospitals. METHODS: In this cross-sectional analysis of a cohort study, we included patients with mild NCIS (National Institutes of Health Stroke Scale score ≤3) who were potentially eligible for DAPT across 168 Florida Stroke Registry participating hospitals between January 2010 and September 2022. Using antiplatelet prescription as the dependent variable (DAPT versus single antiplatelet therapy), we fit logistic regression models adjusted for patient-related factors, hospital-related factors, clinical presentation, vascular risk factors, and ischemic stroke subtype, to obtain adjusted odds ratios (aORs) with 95% CIs. RESULTS: From 283 264 Florida Stroke Registry ischemic stroke patients during the study period, 109 655 NCIS were considered eligible. Among these, 37 058 patients with National Institutes of Health Stroke Scale score >3 were excluded, resulting in a sample of 72 597 mild NCIS (mean age 68±14 years; female 47.3%). Overall, 24 693 (34.0%) patients with mild NCIS were discharged on DAPT and 47 904 (66.0%) on single antiplatelet therapy. DAPT prescription increased from 25.7% in 2010 to 52.8% in 2022 (β/year 2.5% [95% CI, 1.5%-3.4%]). Factors associated with DAPT prescription were premorbid antiplatelet therapy (aOR, 4.66 [95% CI, 2.20-9.88]), large-artery atherosclerosis (aOR, 1.68 [95% CI, 1.43-1.97]), diabetes (aOR, 1.29 [95% CI, 1.13-1.47]), and hyperlipidemia (aOR, 1.24 [95% CI, 1.10-1.39]), whereas female sex (aOR, 0.83 [95% CI, 0.75-0.93]), being non-Hispanic Black patients (compared with non-Hispanic White patients; aOR, 0.78 [95% CI, 0.68-0.90]), admission to a Thrombectomy-capable Stroke Center (compared with Comprehensive Stroke Center; aOR, 0.78 [95% CI, 0.66-0.92]), time-to-presentation 1 to 7 days from last seen well (compared with <24 h; aOR, 0.86 [95% CI, 0.76-0.96]), and small-vessel disease stroke (aOR, 0.81 [95% CI, 0.72-0.94]) were associated with not receiving DAPT at discharge. CONCLUSIONS: Despite a temporal trend increase in DAPT prescription after mild NCIS, we found substantial underutilization of evidence-based DAPT associated with significant disparities in stroke care.
引用
- Del Brutto VJ, Yin R, Gardener H, et al. Determinants and Temporal Trends of Dual Antiplatelet Therapy After Mild Noncardioembolic Stroke. Stroke. 2023. PMID: 37675611. doi:10.1161/STROKEAHA.123.043769
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。